tbuckley/cabot-search huggingface dataset:
French drug lottery idea causes uproar
Authors: A. Dorozynski
Journal: BMJ (1996)

A proposal by the National Aids Council, an advisory body to the French government, that HIV positive people should take part in a lottery to decide whether they should be treated with a new drug has been rejected as unacceptable by prime minister Alain Juppe. Ritonavir, an antiprotease drug developed by Abbott Laboratories in the United States, will not be immediately available in a large enough quantity to treat the 15000 French …
Nazi Origins of an Anatomy Text: The Pernkopf Atlas
Authors: Richard S. Panush
Journal: JAMA (1996)

<h3>To the Editor.</h3> —We recently found that our library contained an anatomy atlas written by a Nazi,<sup>1</sup>brought to our attention after reading of Ernst's reference to it in his account of events at the University of Vienna in 1938.<sup>2</sup>There are compelling allegations that the author of the atlas, Eduard Pernkopf, an ardent Nazi,<sup>2-5</sup>used material obtained from Nazi victims in the atlas.<sup>2-4</sup>After finding Pernkopf' s atlas in our medical library, our institution, with a medical staff of 1116 members, decided to expunge it from our collection and retain it in a symbolic manner, to remember those events in those times and their lessons.<sup>5</sup> The Pernkopf anatomy atlas is extant, however, and is now actively sold and distributed by Urban &amp; Schwarzenberg. The president and chief executive officer of Waverly Inc, the parent company of Urban &amp; Schwarzenberg and Williams &amp; Wilkins, has indicated, in conversations
Dermatology in the intensive care unit
Authors: M.G.S. DUNNILL, S.E. HANDFIELD-JONES, D. TREACHER, D.H. MCGIBBON
Journal: British Journal of Dermatology (2006)

We report our experience, and review the literature, concerning 'intensive care dermatology'. Over a period of 14 months, 27 patients who had significant cutaneous problems were seen in the intensive care unit. These included primary dermatological conditions, multisystem disorders with cutaneous signs, complications of dermatological therapy, and skin conditions developing as complications of intensive care. We discuss the diagnosis and management of dermatological problems in the intensive care unit.
General Networks for Central Terminals in Electrocardiography and Vectorcardiography
Authors: NATHAN MARCHAND, STANLEY A. BRILLER, CHARLES E. KOSSMANN
Journal: Circulation (1955)

A method is described for obtaining true orthogonal components of the heart vector by measuring the differences in potential between resistor networks which are connected to the limbs and to the back. The values of the resistors in the networks are determined by solving equations into which the scalar coefficients for the limbs and for the back are inserted.
Cerebral Embolization During Transcatheter Aortic Valve Implantation
Authors: Philipp Kahlert, Fadi Al-Rashid, Philipp Döttger, Kathrine Mori, Björn Plicht, Daniel Wendt, Lars Bergmann, Eva Kottenberg, Marc Schlamann, Petra Mummel, Dagny Holle, Matthias Thielmann, Heinz G. Jakob, Thomas Konorza, Gerd Heusch, Raimund Erbel, Holger Eggebrecht
Journal: Circulation (2012)

Transcatheter aortic valve implantation (TAVI) is associated with a higher risk of neurological events for both the transfemoral and transapical approach than surgical valve replacement. Cerebral magnetic resonance imaging has revealed more new, albeit clinically silent lesions from procedural embolization, yet the main source and predominant procedural step of emboli remain unclear.Eighty-three patients underwent transfemoral (Medtronic CoreValve [MCV(TF)], n=32; Edwards Sapien [ES(TF)], n=26) and transapical (ES(TA): n=25) TAVI. Serial transcranial Doppler examinations before, during, and 3 months after TAVI were used to identify high-intensity transient signals (HITS) as a surrogate for microembolization. Procedural HITS were detected in all patients, predominantly during manipulation of the calcified aortic valve while stent valves were being positioned and implanted. The balloon-expandable ES prosthesis caused significantly more HITS (mean [95% CI]) during positioning (ES(TF), 259.9 [184.8-334.9]; ES(TA), 206.1[162.5-249.7]; MCV(TF), 78.5 [25.3-131.6]; P<0.001) and the self-expandable MCV prosthesis during implantation (MCV(TF), 397.1 [302.1-492.2]; ES(TF), 88.2 [70.2-106.3]; ES(TA), 110.7 [82.0-139.3]; P<0.001). Overall, there were no significant differences between transfemoral and transapical TAVI or between the MCV and ES prostheses. No HITS were detected at baseline or 3-month follow-up. There was 1 major procedural stroke that resulted in death and 1 minor procedural stroke with full recovery at 3-month follow-up in the MCV group.Procedural HITS were detected by transcranial Doppler in all patients. Although no difference was observed between the transfemoral and the transapical approach with the balloon-expandable ES stent valve, transfemoral TAVI with the self-expandable MCV prosthesis resulted in the greatest number of HITS, predominantly during implantation.
Harms of Cognitive Behaviour Therapy Designed to Increase Activity Levels in Chronic Fatigue Syndrome: Questions Remain
Authors: Tom Kindlon
Journal: Psychotherapy and Psychosomatics (2011)

Letters| January 04 2011 Harms of Cognitive Behaviour Therapy Designed to Increase Activity Levels in Chronic Fatigue Syndrome: Questions Remain Subject Area: Psychiatry and Psychology Tom Kindlon Tom Kindlon Irish ME/CFS Association, Dublin, Ireland Search for other works by this author on: This Site PubMed Google Scholar Psychother Psychosom (2011) 80 (2): 110–111. https://doi.org/10.1159/000320778 Article history Received: June 25 2010 Accepted: August 26 2010 Published Online: January 04 2011 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation Tom Kindlon; Harms of Cognitive Behaviour Therapy Designed to Increase Activity Levels in Chronic Fatigue Syndrome: Questions Remain. Psychother Psychosom 1 February 2011; 80 (2): 110–111. https://doi.org/10.1159/000320778 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsPsychotherapy and Psychosomatics Search Advanced Search Article PDF first page preview Close Modal This content is only available via PDF. © 2010 S. Karger AG, Basel2011Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. You do not currently have access to this content.
Somebody cut my brain in half with a Sabatier knife
Authors: Kieran Walsh
Journal: BMJ (2006)

“The moment I first realised that my world had changed was just after I'd finished a busy surgery and I went out to have a conversation with one of the receptionists and I started to feel very odd. I felt as though somebody had taken a Sabatier knife and cut my brain in half. I felt disconnected and unplugged and I knew at that moment, that this was something major.” Dr Chris Manning is a former general practitioner and also a patient—he has had severe depression, and this is how he first realised that something was …
Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure
Authors: Dominique Thabut, Julien Massard, Alice Gangloff, Nicolas Carbonell, Claire Francoz, Eric Nguyen-Khac, Christian Duhamel, Didier Lebrec, Thierry Poynard, Richard Moreau
Journal: Hepatology (2007)

Although it is often functional at presentation, acute renal failure has a poor prognosis in patients with cirrhosis. The role of inflammation, a key event in the outcome of cirrhosis, has never been studied in this setting. We aimed to investigate the predictive factors of mortality in patients with cirrhosis and acute functional renal failure, specifically in relation to inflammatory events. One hundred consecutive patients with cirrhosis from 5 French hospitals were prospectively included at the day of onset of acute renal failure. Medical history, treatments, and procedures during the month before inclusion were recorded. Physical examination, blood and urinary chemistries, and renal ultrasound examination were performed. The presence of systemic inflammatory response syndrome (SIRS), infection, and sepsis was assessed. The primary outcome was in-hospital mortality. The mechanism of renal failure was functional in 83 patients. Causes of renal failure were hypovolemia (34%), hepatorenal syndrome without ongoing infection (17%), hepatorenal syndrome with ongoing infection (16%), nephrotoxicity (2%), and multifactorial (31%). SIRS was observed in 41% of patients, 56% of them with infection. In-hospital mortality was 68% in patients with SIRS and 33% in patients without ( P = 0.001). In multivariate analysis, only model for end-stage liver disease score and presence of SIRS, but not infection, remained associated with a poor outcome. Conclusion: The presence of SIRS, with or without infection, is a major independent prognostic factor in patients with cirrhosis and acute functional renal failure. This suggests that preventing and treating SIRS could decrease mortality in patients with cirrhosis and acute renal failure. (Hepatology 2007.)
Fear conditioning enhances short-latency auditory responses of lateral amygdala neurons: Parallel recordings in the freely behaving rat
Authors: Gregory J. Quirk, J. Christopher Repa, Joseph E. LeDoux
Journal: Neuron (1995)

The lateral nucleus of the amygdala (LA) is the first site in the amygdala where the plasticity underlying fear conditioning could occur. We simultaneously recorded from multiple LA neurons in freely moving rats during fear conditioning trials in which tones were paired with foot shocks. Conditioning significantly increased the magnitude of tone-elicited responses (often within the first several trials), converted unresponsive cells into tone-responsive ones, and altered functional couplings between LA neurons. The effects of conditioning were greatest on the shortest latency (less than 15 ms) components of the tone-elicited responses, consistent with the hypothesis that direct projections from the auditory thalamus to LA are an important link in the circuitry through which rapid behavioral responses are controlled in the presence of conditioned fear stimuli.
Renal Denervation in Moderate Treatment-Resistant Hypertension
Authors: Christian Ott, Felix Mahfoud, Axel Schmid, Tilmann Ditting, Paul A. Sobotka, Roland Veelken, Aline Spies, Christian Ukena, Ulrich Laufs, Michael Uder, Michael Böhm, Roland E. Schmieder
Journal: Journal of the American College of Cardiology (2013)
Calmodulin level in whole blood correlates with the percentage of reticulocytes
Authors: James A. Warth, George J. Brewer, Margaret E. Gnegy, Glen Treisman, Karen Near
Journal: American Journal of Hematology (1983)

Abstract We studied the calmodulin‐like activity (CaM) level in hemolyzed samples of whole blood after determining the percentage and absolute number of reticulocytes present. Twenty‐six samples from 25 people with a range of reticulocyte counts were studied. CaM levels correlated with the percentage (r = 0.63, P &lt; .01) and absolute number (r = 0.64, P &lt; .01) of reticulocytes present, indicating that the calmodulin‐like activity level in whole blood was inversely related to erythrocyte age.
Ranitidine-acetaminophen interaction: Effects on acetaminophen-induced hepatotoxicity in fischer 344 rats
Authors: Thomas B. Leonard, D. Gwyn Morgan, John G. Dent
Journal: Hepatology (1985)

Cimetidine has been shown to protect against acetaminophen-mediated hepatotoxicity in both rats and mice. In contrast to cimetidine, ranitidine recently has been determined to potentiate the hepatotoxic action of acetaminophen in Fischer 344 rats. The present studies were designed to characterize this ranitidine-acetaminophen interaction. Acetaminophen administration (750 mg per kg, p.o.) to F344 rats produced maximal hepatic necrosis, 24 hr after treatment, as assessed by SGPT activity and histopathology. Ranitidine pretreatment 30 min prior to acetaminophen treatment increased the toxicity but did not alter its course. Ranitidine administration (50 mg per kg) enhanced acetaminophen hepatotoxicity throughout the toxic dose range of acetaminophen (600 to 1,000 mg per kg) and potentiation of acetaminophen hepatotoxicity by ranitidine was dose-dependent. Maximal increases were observed at 50 mg per kg ranitidine whereas, doses of ranitidine greater than 100 mg per kg inhibited acetaminophen toxicity. SGPT data were corroborated by histopathologic evaluation. Ranitidine was not intrinsically hepatotoxic when administered alone (500 mg per kg), or following glutathione depletion, or after induction of hepatic mixed-function oxidase activity. The results obtained in these studies support the suggestion that, at high doses (>100 mg per kg), ranitidine reduces acetaminophen hepatotoxicity by reducing metabolic activation, while at lower doses ranitidine potentiates acetaminophen hepatotoxicity. Inhibition by ranitidine of acetaminophen conjugation is proposed as a possible mechanism of this potentiation.
Icterus and Febrile Reactions in Response to Isonicotinic Acid Hydrazine
Authors: Edgar Haber, Robert K. Osborne
Journal: New England Journal of Medicine (1959)

ISONICOTINIC acid hydrazine is a drug remarkably free of toxic reactions at the dosage levels ordinarily employed. The most common side effects relate to Central-nervous-system hyperexcitability and peripheral neuropathy.1 Drug fever and jaundice are infrequently reported, only a few documented cases of each being found in the literature. However, these toxic reactions are not uncommonly associated with para-aminosalicylic acid administration.2 Since this drug is often given together with isonicotinic acid hydrazine, it is of some importance to point out that certain of the side effects of both drugs may be similar.It was noted in early animal experiments that long-term . . .
Expression of nm23-H1 Is Associated with Poor Prognosis in Peripheral T-Cell Lymphoma, Not Otherwise Specified
Authors: Nozomi Niitsu, Hirokazu Nakamine, Masataka Okamoto
Journal: Clinical Cancer Research (2011)

Abstract Purpose: We examined whether nm23-H1 is a prognostic factor of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). Experimental Design: We studied 102 consecutive, untreated PTCL-NOS patients from 1998 to 2008. The expression of nm23-H1 and TIA-1 was studied by immunohistochemistry. Results: nm23-H1 was positive in 44.1% and TIA-1 in 78.4% of the PTCL-NOS patients. nm23-H1 expression was not correlated with age, performance status (PS), lactate dehydrogenase (LDH) level, or stage but was significantly correlated with the prognostic index for T-cell lymphoma. The serum nm23-H1 level was 43.44 ng/mL in the cytoplasmic nm23-H1 strongly positive, 24.32 ng/mL in the cytoplasmic nm23-H1 moderately positive, and 13.64 ng/mL in the cytoplasmic nm23-H1–negative patients. The nm23-H1–positive group had significantly shorter overall survival (OS). TIA-1 had no prognostic impact on 5-year OS rates. OS was significantly shorter in patients with the following clinicopathologic features: age 60 or more years, PS of 2 to 4, LDH level greater than normal, bone marrow involvement, or nm23-H1–positive lymphoma. Multivariate analysis confirmed nm23-H1 expression to be an independent prognostic factor. Conclusions: The nm23-H1 protein may be an important prognostic factor in PTCL-NOS. Because our results suggested that nm23-HI is produced by lymphoma cells, we expect to see the development of new treatments targeting nm23 overexpression. Clin Cancer Res; 17(9); 2893–9. ©2011 AACR.
Vinblastine for Adult Histiocytosis X
Authors: Forest S. Tennant
Journal: JAMA (1969)

<h3>To the Editor:—</h3> To the best of my knowledge, in 1966The Journal(<b>197</b>:403, 1966) described the only reported case of adult, disseminated histiocytosis X to be treated with inin- travenously administered vinblastine sulfate. Although vinblastine was probably beneficial in that case, since little evidence of histiocytic proliferation was discovered at autopsy, corticosteroids had been simultaneously administered making it difficult to fully assess the individual drug's therapeutic value. Prior to report, intravenous administration of vinblastine had only been found to produce remissions in certain childhood varieties of histiocytosis X.<sup>1,2</sup>In order to clarify the role of vinblastine therapy in treating adult, disseminated histiocytosis X, the following case, in which this therapy appeared to be life saving, is briefly described. <h3>Report of a Case:—</h3> A 54-year old man who had a histologically proven four-year history of disseminated histiocytosis X was admitted on July 8, 1968, due to a 22.7-kg
FURTHER STUDIES ON THE BLOOD AND THE HEMATOPOIETIC TISSUES IN MALIGNANT PANLEUCOPENIA OF CATS
Authors: William D. Hammon, John F. Enders
Journal: The Journal of Experimental Medicine (1939)

The most conspicuous clinical finding during the course of this virus disease is a fulminating panleucopenia. The earliest significant decrease noted is usually in the number of the lymphocytes. From the study of lymph nodes and bone marrow during the incubation period and throughout the illness, it appears that failure of leucopoiesis is the cause of leucopenia. Inclusion bodies in the primitive blood cells of the marrow suggest a direct action of the virus on these cells. When recovery occurs a marked myelogenous leucemoid response is noted. Available data indicate the presence of a mild anemia due to a failure in erythropoiesis, less marked than the leucopenia probably because of the longer life of the adult circulating erythrocytes. The erythrocytes appear to have an increased fragility and the serum has a slight increase in icterus, suggesting an increased mean erythrocyte age. During recovery erythropoiesis does not begin until after the myeloid marrow response has begun to subside, due possibly to previous mechanical crowding of the marrow by the more rapidly growing myeloblasts and myelocytes.
Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro.
Authors: L M Slater, P Sweet, M Stupecky, S Gupta
Journal: Journal of Clinical Investigation (1986)

The development of drug resistance by tumor cells is a major obstacle to the cure of human malignancy. Cyclosporin A (CsA) completely reverses primary resistance to vincristine and cross resistance to daunorubicin in a pleiotropic drug-resistant subline of human T cell acute lymphatic leukemia. This subline is over 50-fold resistant to vincristine and fivefold resistant to daunorubicin. CsA has little effect on vincristine or daunorubicin activity in drug-sensitive parental leukemia and corrects daunorubicin resistance without altering cellular daunorubicin accumulation.
Superior Mesenteric Artery Syndrome
Authors: Jacob Rabinovitch
Journal: JAMA (1962)

Only 12 cases of superior mesenteric artery syndrome in the young have been reported in the literature available to the authors. Three new cases form the basis of the present paper. Abdominal discomfort, pain, and vomiting of bilestained material constituted the majority of complaints, but the signs and symptoms varied with the age of onset and degree of intestinal obstruction. The syndrome is characterized by partial or complete obstruction of the third part of the duodenum. The obstruction results from the pressure of structures in the root of the mesentery, especially the superior mesenteric neurovascular bundle, upon the duodenum. For mild cases, the authors recommend a trial of medical therapy; for severe cases they recommend duodeno jejunostomy.
New safeguards planned for psychiatric patients
Authors: C. Dyer
Journal: BMJ (1998)

The Department of Health is expected to introduce new safeguards for psychiatric patients admitted informally to hospitals and residential homes, after a House of Lords ruling last week which was greeted with huge relief by NHS managers and psychiatrists.

Five law lords ruled unanimously that a 48 year old autistic man, L, was not unlawfully detained after he was admitted informally to Bournewood Hospital in Surrey. The ruling overturned a decision last December by the Court of Appeal that caused consternation in the health service and forced doctors to section under the Mental Health Act thousands of patients with learning disabilities and dementia (14 February, p 497). The appeal court held that the long standing practice of informally admitting …